You are here

  • Home
  • Archive
  • Volume 79, Issue 8
  • Adalimumab dose tapering in patients with rheumatoid arthritis who are in long-standing clinical remission: results of the phase IV PREDICTRA study

Article metrics

Article menu

Download PDFPDF

XML
Rheumatoid arthritis
Adalimumab dose tapering in patients with rheumatoid arthritis who are in long-standing clinical remission: results of the phase IV PREDICTRA study

 

Online download statistics by month:

Online download statistics by month: May 2020 to October 2024

AbstractFullPdf
May 2020839831290
Jun 202030229978
Jul 2020775786214
Aug 2020363358186
Sep 202019618992
Oct 202014814367
Nov 202011311138
Dec 2020807728
Jan 20211019439
Feb 2021626220
Mar 202113513041
Apr 2021818036
May 2021706822
Jun 2021565521
Jul 2021484510
Aug 2021797725
Sep 2021595821
Oct 2021989315
Nov 2021737132
Dec 2021545018
Jan 2022777610
Feb 2022919014
Mar 202210310014
Apr 20221019429
May 2022918811
Jun 202210410213
Jul 2022707015
Aug 202296967
Sep 2022999642
Oct 202292875
Nov 202281798
Dec 202271679
Jan 202312312018
Feb 202387869
Mar 202352516
Apr 2023605813
May 2023676512
Jun 2023666215
Jul 2023828525
Aug 2023807814
Sep 202310510618
Oct 202311510913
Nov 20231071068
Dec 202396915
Jan 202434318
Feb 2024625210
Mar 202412511626
Apr 202483786
May 2024494313
Jun 2024626010
Jul 2024837917
Aug 2024666412
Sep 202467626
Oct 202437339
Total651663571743